| NCT02115581 |
Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy |
Dilated Cardiomyopathy |
Drug: Coenzyme Q10|Drug: Placebo |
| NCT01150461 |
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy |
Hypertrophic Cardiomyopathy |
Drug: losartan|Drug: placebo |
| NCT00629018 |
Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy |
Dilated Cardiomyopathy |
Biological: CD34+ autologous stem cell transplantation|Drug: Bone Marrow Stimulation|Biological: SC therapy |
| NCT01432626 |
Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG |
Stress Induced Cardiomyopathy |
Drug: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging |
| NCT01392625 |
PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study) |
Non-ischemic Dilated Cardiomyopathy |
Biological: Autologous hMSCs|Biological: Allogeneic hMSCs |
| NCT00694161 |
The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy |
Cardiomyopathy |
Drug: Fx-1006A |
| NCT00319982 |
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem |
Hypertrophic Cardiomyopathy |
Drug: Diltiazem|Drug: Placebo |
| NCT01982695 |
Cardiomyopathy in DMD: Lisinopril vs. Losartan |
Duchenne Muscular Dystrophy (DMD)|Cardiomyopathy |
Drug: Losartan|Drug: Lisinopril |
| NCT00696410 |
The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy |
Heart Failure|Cardiomyopathies |
Drug: Zinc Acetate |
| NCT01721967 |
Ranolazine for the Treatment of Chest Pain in HCM Patients |
Hypertrophic Cardiomyopathy |
Drug: Ranolazine |
| NCT01345188 |
Ranolazine in Ischemic Cardiomyopathy |
Cardiomyopathy|Chest Pain|Dyspnea |
Drug: Ranexa|Drug: Placebo |
| NCT01223703 |
PUFAs and Left Ventricular Function in Heart Failure |
Dilated Cardiomyopathy|Heart Failure |
Drug: n-3 PUFAs|Drug: Placebo |
| NCT01217827 |
Implantable Cardioverter-Defibrillator Use in the VA System |
Cardiomyopathies |
Behavioral: Clinical Reminder |
| NCT00599014 |
Heart Failure Study: The Atlanta Cardiomyopathy Consortium |
Heart Failure |
|
| NCT01604122 |
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers |
Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP)|Transthyretin Cardiomyopathy (TTR-CM)|Familial Amyloid Cardiomyopathy|Senile Systemic Amyloidosis (SSA) |
Other: No drug |
| NCT02027883 |
Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD) |
Cardiomyopathy |
Device: Nominal T shock setting|Device: Educated T shock setting |
| NCT00203203 |
Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF) |
Ischemic Cardiomyopathy |
Device: Intramyocardial Injection of stem cells via NOGA Mapping|Other: Control, then Stem Cell Therapy |
| NCT00180323 |
ACC - Atrial Contribution to CRT |
Dilated Cardiomyopathy |
Device: Renewal |
| NCT01798992 |
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart |
Idiopathic Dilated Cardiomyopathy |
Drug: Carvedilol|Drug: Metoprolol succinate|Drug: Metoprolol succinate + doxazosin |
| NCT01989195 |
Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease |
ISCHEMIC CARDIOMYOPATHY |
Drug: 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT |
| NCT01521546 |
Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy |
Duchenne Muscular Dystrophy |
Drug: eplerenone|Drug: placebo |
| NCT01391507 |
Pilot Study of COR-1 in Heart Failure |
Cardiomyopathy, Dilated |
Drug: 0.9 % sodium chloride|Drug: COR-1|Drug: Standard therapy for heart failure |
| NCT00589836 |
Assessment of Left Ventricular Torsion by Echocardiography Study |
Hypertrophic Cardiomyopathy |
|
| NCT02319005 |
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) |
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related|Familial Transthyretin Cardiac Amyloidosis |
Drug: Revusiran (ALN-TTRSC)|Drug: Sterile Normal Saline (0.9% NaCl) |
| NCT00273182 |
InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry |
Heart Failure|Cardiomyopathy |
Device: InSync Model 8040|Device: InSync III Model 8042 |
| NCT00741156 |
The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution |
Hypertension|Congestive Cardiomyopathy |
Drug: Enalaprilat |
| NCT00583661 |
Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device |
Heart Failure|Cardiomyopathies |
Device: EXCOR Pediatric |
| NCT00252187 |
Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure |
Congestive Heart Failure|Cardiomyopathy |
Drug: B-type Natriuretic Peptide (BNP)|Other: Placebo |
| NCT00454818 |
Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure |
Heart Failure, Congestive|Dilated Cardiomyopathy |
Genetic: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|Procedure: Placebo Infusion|Genetic: MYDICAR Phase 2 (Placebo-controlled, Randomized Study) |
| NCT01215253 |
Ranolazine Implantable Cardioverter-Defibrillator Trial |
Ischemic Cardiomyopathy|Nonischemic Cardiomyopathy|Heart Failure |
Drug: Ranolazine |
| NCT01736566 |
A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare |
Healthy Adults (Full Study and Extension Phase)|Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy |
Other: Family History + Whole Genome Sequencing|Other: Family History Only |
| NCT00682565 |
PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina |
Heart Failure|Myocardial Ischemia|Angina Pectoris |
Drug: CK-1827452 24mg and 6 mg iv infusion|Drug: CK-1827452 12.5mg capsule|Drug: CK-1827452 48 mg and 11 mg iv infusion|Drug: CK-1827452 25mg capsule|Drug: Placebo iv infusion|Drug: Placebo capsule |
| NCT03225001 |
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - Nested Registry 3/Valve-in-Valve |
Aortic Stenosis|Cardiomyopathy, Hypertrophic |
Device: Edwards SAPIEN XT transcatheter valve, Model 9300TFX |
| NCT00904982 |
Randomized Trial of Interventions to Improve Warfarin Adherence |
Atrial Fibrillation|Deep Vein Thrombosis|Dilated Cardiomyopathies |
Behavioral: Financial Incentive and Med-eMonitor|Device: 2Med-eMonitor |
| NCT01983293 |
CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients |
Non-left Bundle Branch Block|Ischemic or Non-ischemic Cardiomyopathy |
Device: QLV based implant strategy|Device: Standard of care implant strategy |
| NCT00824005 |
Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study) |
Chronic Ischemic Heart Disease|Left Ventricular Dysfunction|Angina|Ischemic Cardiomyopathy |
Biological: Adult stem cells|Biological: Placebo |
| NCT01442129 |
The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation |
Heart Failure|Cardiomyopathy|Ventricular Dysfunction |
Biological: MPC Intramyocardial injection|Biological: Control Solution |
| NCT00121485 |
Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy |
Heart Failure, Congestive|Ventricular Dysfunction|Cardiomyopathies |
Device: Left Ventricular Assist System (LVAS) |
| NCT00121472 |
Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation |
Heart Failure, Congestive|Ventricular Dysfunction|Cardiomyopathies |
Device: Thoratec HeartMate II Left Ventricular Assist System (LVAS) |
| NCT00626028 |
Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing |
Idiopathic Pulmonary Arterial Hypertension|Congenital Heart Disease With Pulmonary Hypertension|Cardiomyopathy |
Drug: Nitric Oxide for inhalation|Drug: Oxygen|Drug: Nitric Oxide plus Oxygen |
| NCT00289276 |
FAST (Fluid Accumulation Status Trial) |
Congestive Heart Failure|Cardiomyopathy|Dyspnea|Pulmonary Edema|Heart Diseases |
Device: Fluid Status Monitoring (OptiVol™) |
| NCT00376532 |
Extracellular Matrix Marker of Arrhythmia Risk (EMMA) |
Myocardiopathies|Ischemia, Myocardial|Arrythmia|Death, Sudden, Cardiac |
|
| NCT00654004 |
Fatty Acid Oxidation Disorders & Body Weight Regulation Grant |
Trifunctional Protein Deficiency |
|
| NCT01113008 |
Remote Ischemic Postconditioning in Humans |
Myocardial Reperfusion Injury |
Procedure: Remote ischemic postconditioning|Procedure: Control group |
| NCT00586820 |
Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI |
Myocardial Reperfusion Injury |
Drug: BQ-123|Drug: Placebo |
| NCT02292186 |
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis |
TTR-mediated Amyloidosis |
Drug: Revusiran (ALN-TTRSC) |
| NCT02170363 |
HeartMate 3™ CE Mark Clinical Investigation Plan |
Advanced Refractory Left Ventricular Heart Failure |
Device: Left Ventricular Assist System (LVAS) |
| NCT00294671 |
The Effect of Diflunisal on Familial Amyloidosis |
Familial Amyloid Polyneuropathy|Familial Amyloidosis |
Drug: diflunisal|Other: placebo |
| NCT00358215 |
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial |
Heart Failure|Anemia|Cardiovascular Disease|Ventricular Dysfunction|Congestive Heart Failure |
Drug: Darbepoetin alfa|Drug: Placebo |